Damora Therapeutics, Inc. Common Stock (DMRA) Expected to Announce Quarterly Earnings on Monday

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) is expected to be posting its Q4 2025 results before the market opens on Monday, March 30th. Analysts expect the company to announce earnings of ($0.14) per share for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Thursday, March 19, 2026 at 7:00 AM ET.

Damora Therapeutics, Inc. Common Stock Stock Down 0.5%

Shares of DMRA opened at $25.50 on Friday. The firm has a market cap of $1.54 billion, a price-to-earnings ratio of -2.11 and a beta of 1.42. The business’s 50 day moving average is $27.02 and its two-hundred day moving average is $19.77. Damora Therapeutics, Inc. Common Stock has a 52-week low of $2.01 and a 52-week high of $38.33.

Analyst Ratings Changes

DMRA has been the subject of a number of research analyst reports. Zacks Research upgraded shares of Damora Therapeutics, Inc. Common Stock to a “hold” rating in a research note on Friday, January 9th. Guggenheim reissued a “buy” rating and set a $40.00 price objective (up from $36.00) on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, February 17th. Lifesci Capital raised shares of Damora Therapeutics, Inc. Common Stock to a “strong-buy” rating in a research report on Monday, February 2nd. Evercore assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research note on Wednesday. They issued an “outperform” rating and a $46.00 target price on the stock. Finally, Leerink Partners assumed coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Wednesday, January 7th. They set an “outperform” rating and a $46.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $44.25.

Hedge Funds Weigh In On Damora Therapeutics, Inc. Common Stock

Several large investors have recently added to or reduced their stakes in the company. Ikarian Capital LLC bought a new stake in Damora Therapeutics, Inc. Common Stock in the 4th quarter valued at about $6,574,000. Jain Global LLC acquired a new position in Damora Therapeutics, Inc. Common Stock during the 4th quarter valued at about $2,774,000. Remedium Capital Partners LLC bought a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth about $2,772,000. Boothbay Fund Management LLC bought a new position in Damora Therapeutics, Inc. Common Stock in the 4th quarter worth about $2,204,000. Finally, Connective Capital Management LLC acquired a new stake in shares of Damora Therapeutics, Inc. Common Stock in the third quarter valued at approximately $100,000. 14.20% of the stock is currently owned by institutional investors.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto Inc is a clinical‐stage biotechnology company developing small‐molecule therapies that target key pathways involved in fibrotic and malignant diseases. The company’s research focuses on inhibiting galectin‐3, an extracellular carbohydrate‐binding protein implicated in inflammation, fibrosis and tumor progression, as well as lysyl oxidase‐like 2 (LOXL2), an enzyme that crosslinks collagen and elastin in fibrotic tissue.

Its lead programs include GB0139, an inhaled galectin‐3 inhibitor in Phase II trials for idiopathic pulmonary fibrosis and other fibrosing lung diseases, and GB1211, an oral galectin‐3 inhibitor being evaluated for systemic fibrotic disorders.